NO963919L - Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler - Google Patents

Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler

Info

Publication number
NO963919L
NO963919L NO963919A NO963919A NO963919L NO 963919 L NO963919 L NO 963919L NO 963919 A NO963919 A NO 963919A NO 963919 A NO963919 A NO 963919A NO 963919 L NO963919 L NO 963919L
Authority
NO
Norway
Prior art keywords
hla
molecules
complex
peptides derived
isolated peptides
Prior art date
Application number
NO963919A
Other languages
English (en)
Norwegian (no)
Other versions
NO963919D0 (no
Inventor
Alan Townsend
Judy Bastin
Thierry Boon-Falleur
Pierre Van Der Bruggen
Pierre Coulie
Thomas Gajewski
Cornelis Melief
M W Visseren
W M Kast
Original Assignee
Ludwig Inst Cancer Res
Univ Oxford
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186 external-priority patent/US5585461A/en
Application filed by Ludwig Inst Cancer Res, Univ Oxford, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of NO963919D0 publication Critical patent/NO963919D0/no
Publication of NO963919L publication Critical patent/NO963919L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO963919A 1994-03-24 1996-09-19 Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler NO963919L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/217,186 US5585461A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/261,160 US5591430A (en) 1994-03-24 1994-06-17 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/290,381 US5851523A (en) 1994-03-24 1994-08-15 Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003657 WO1995025740A1 (en) 1994-03-24 1995-03-22 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Publications (2)

Publication Number Publication Date
NO963919D0 NO963919D0 (no) 1996-09-19
NO963919L true NO963919L (no) 1996-11-20

Family

ID=27396385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963919A NO963919L (no) 1994-03-24 1996-09-19 Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler

Country Status (16)

Country Link
US (1) US5851523A (zh)
EP (2) EP0960622A3 (zh)
JP (1) JP3536179B2 (zh)
CN (1) CN1151170C (zh)
AT (1) ATE198336T1 (zh)
AU (1) AU698781B2 (zh)
CA (1) CA2186004C (zh)
DE (1) DE69519748T2 (zh)
DK (1) DK0804483T3 (zh)
ES (1) ES2154728T3 (zh)
FI (1) FI963779A0 (zh)
GR (1) GR3035636T3 (zh)
NO (1) NO963919L (zh)
NZ (1) NZ283587A (zh)
PT (1) PT804483E (zh)
WO (1) WO1995025740A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
DE69610483T2 (de) * 1996-01-18 2001-06-13 Aventis Pharma Deutschland Gmbh In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen
CA2295321C (en) * 1997-06-23 2008-01-29 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
EP1905832A3 (en) * 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
ATE389019T1 (de) * 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
KR20020047249A (ko) * 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
JP4668919B2 (ja) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド 修飾ｃｅａ／ｂ７ベクター
AU2008303948A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide Asn-Asp-Asp-Cys-Glu- Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu alone or in combination with the peptide Thr-Thr-Ser-Gln-Val- Arg-Pro-Arg as a therapeutic agent
CN106117334B (zh) * 2016-06-24 2020-02-11 秦皇岛未名健康城开发有限公司 一种肿瘤抗原mage3的ctl识别表位肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses

Also Published As

Publication number Publication date
CA2186004A1 (en) 1995-09-28
DE69519748T2 (de) 2001-10-18
EP0960622A3 (en) 1999-12-22
NZ283587A (en) 1998-04-27
NO963919D0 (no) 1996-09-19
CN1151170C (zh) 2004-05-26
FI963779A (fi) 1996-09-23
ATE198336T1 (de) 2001-01-15
AU2192895A (en) 1995-10-09
GR3035636T3 (en) 2001-06-29
JP3536179B2 (ja) 2004-06-07
EP0804483A1 (en) 1997-11-05
EP0804483A4 (en) 1998-05-20
WO1995025740A1 (en) 1995-09-28
ES2154728T3 (es) 2001-04-16
US5851523A (en) 1998-12-22
DE69519748D1 (de) 2001-02-01
CA2186004C (en) 2008-09-23
PT804483E (pt) 2001-06-29
DK0804483T3 (da) 2001-02-12
EP0960622A2 (en) 1999-12-01
EP0804483B1 (en) 2000-12-27
FI963779A0 (fi) 1996-09-23
JPH10504518A (ja) 1998-05-06
AU698781B2 (en) 1998-11-05
CN1150805A (zh) 1997-05-28

Similar Documents

Publication Publication Date Title
NO963919L (no) Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
PL374311A1 (en) Methods for purifying protein
ES2129622T3 (es) Receptores para interleuquina-10 de mamifero.
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE69824719D1 (de) Cytokinähnlicher faktor-7 aus säugetieren
SE9602496D0 (sv) Method and means for producing a fibrinogen binding protein and its use in biotechnology
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
DE69735583D1 (de) Semisynthetisches verfahren zur herstellung von didemninanalogen
DE60025704D1 (de) Das goodpasture-antigen bindende protein
FI970071A0 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
DE69128039D1 (de) Allergene aus roggenspreupollen
EP0990703A4 (en) NEW POLYPEPTIDE, FOR CODING DNA AND THEIR USE
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
BR9911609A (pt) Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof